Krishnan Thirumoorthy

Dr. Krishnan Thirumoorthy

Vellore Institute of Technology (VIT) Vellore
orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 2017 in Cancer Research
Verified
Journal Article
Open access
PDF file
MCMoumita Chatterjee
Moumita Chatterjee
EBEdgar Ben-Josef
Edgar Ben-Josef
RRRyan Robb
Ryan Robb
MVMarall Vedaie
Marall Vedaie
SSStar Seum
Star Seum
TWTerence Williams
Terence Williams
Nab-paclitaxel, a nanoparticle conjugate of paclitaxel to human albumin, exhibits efficacy in pancreatic cancer, non–small cell lung cancer and breast cancer. However, there is a lack of predictive biomarkers to identify patients who might benefit most from its administration. This study addresses this gap in knowledge by identifying that caveolin-1 (Cav-1) is a candidate mechanism-based biomarker. Caveolae are small membrane invaginations important for transendothelial albumin uptake. Cav-1, the principal structural component of caveolae, is overexpressed in the cancers noted above that respond to nab-paclitaxel. Thus, we hypothesized that Cav-1 may be critical for albumin uptake in tumors and perhaps determine their response to this drug. Cav-1 protein levels correlated positively with nab-paclitaxel sensitivity. RNAi-mediated attenuation of Cav-1 expression reduced uptake of albumin and nab-paclitaxel in cancer cells and rendered them resistant to nab-paclitaxel–induced apoptosis. Conversely, Cav-1 overexpression enhanced sensitivity to nab-paclitaxel. Selection for cellular resistance to nab-paclitaxel in cell culture correlated with a loss of Cav-1 expression. In mouse xenograft models, cancer cells, where Cav-1 was attenuated, exhibited resistance to the antitumor effects of nab-paclitaxel therapy. Overall, our findings suggest Cav-1 as a predictive biomarker for the response to nab-paclitaxel and other albumin-based cancer therapeutic drugs. Cancer Res; 77(21); 5925–37. ©2017 AACR.

30 April 2017 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
KPKamalakannan Palanichamy
Kamalakannan Palanichamy
SKSuman Kanji
Suman Kanji
NGNicolaus Gordon
Nicolaus Gordon
KTKrishnan Thirumoorthy
Krishnan Thirumoorthy
JJJohn R. Jacob
John R. Jacob
ACArnab Chakravarti
Arnab Chakravarti
Purpose: To identify potential molecular hubs that regulate oncogenic kinases and target them to improve treatment outcomes for glioblastoma patients. Experimental Design: Data mining of The Cancer Genome Atlas datasets identified nicotinamide-N-methyl transferase (NNMT) as a prognostic marker for glioblastoma, an enzyme linked to the reorganization of the methylome. We tested our hypothesis that NNMT plays a crucial role by modulating protein methylation, leading to inactivation of tumor suppressors and activation of oncogenes. Further experiments were performed to understand the underlying biochemical mechanisms using glioblastoma patient samples, established, primary, and isogenic cells. Results: We demonstrate that NNMT outcompetes leucine carboxyl methyl transferase 1 (LCMT1) for methyl transfer from principal methyl donor SAM in biological systems. Inhibiting NNMT increased the availability of methyl groups for LCMT1 to methylate PP2A, resulting in the inhibition of oncogenic serine/threonine kinases (STK). Further, NNMT inhibition retained the radiosensitizer nicotinamide and enhanced radiation sensitivity. We have provided the biochemical rationale of how NNMT plays a vital role in inhibiting tumor suppressor PP2A while concomitantly activating STKs. Conclusions: We report the intricate novel mechanism in which NNMT inhibits tumor suppressor PP2A by reorganizing the methylome both at epigenome and proteome levels and concomitantly activating prosurvival STKs. In glioblastoma tumors with NNMT expression, activation of PP2A can be accomplished by FDA approved perphenazine (PPZ), which is currently used to treat mood disorders such as schizophrenia, bipolar disorder, etc. This study forms a foundation for further glioblastoma clinical trials using PPZ with standard of care treatment. Clin Cancer Res; 23(9); 2325–34. ©2016 AACR.

14 July 2016 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
KPKamalakannan Palanichamy
Kamalakannan Palanichamy
KTKrishnan Thirumoorthy
Krishnan Thirumoorthy
SKSuman Kanji
Suman Kanji
NGNicolaus Gordon
Nicolaus Gordon
RSRajbir Singh
Rajbir Singh
ACArnab Chakravarti
Arnab Chakravarti
Purpose: We employed a metabolomics-based approach with the goal to better understand the molecular signatures of glioblastoma cells and tissues, with an aim toward identifying potential targetable biomarkers for developing more effective and novel therapies. Experimental Design: We used liquid chromatography coupled with mass spectrometry (LC-MS/Q-TOF and LC-MS/QQQ) for the discovery and validation of metabolites from primary and established glioblastoma cells, glioblastoma tissues, and normal human astrocytes. Results: We identified tryptophan, methionine, kynurenine, and 5-methylthioadenosine as differentially regulated metabolites (DRM) in glioblastoma cells compared with normal human astrocytes (NHAs). Unlike NHAs, glioblastoma cells depend on dietary methionine for proliferation, colony formation, survival, and to maintain a deregulated methylome (SAM:SAH ratio). In methylthioadenosine phosphorylase (MTAP)-deficient glioblastoma cells, expression of MTAP transgene did not alter methionine dependency, but compromised tumor growth in vivo. We discovered that a lack of the kynurenine-metabolizing enzymes kynurenine monooxygenase and/or kynureninase promotes the accumulation of kynurenine, which triggers immune evasion in glioblastoma cells. In silico analysis of the identified DRMs mapped the activation of key oncogenic kinases that promotes tumorigenesis in glioblastoma. We validated this result by demonstrating that the exogenous addition of DRMs to glioblastoma cells in vitro results in oncogene activation as well as the simultaneous downregulation of Ser/Thr phosphatase PP2A. Conclusions: We have connected a four-metabolite signature, implicated in the methionine and kynurenine pathways, to the promotion and maintenance of glioblastoma. Together, our data suggest that these metabolites and their respective metabolic pathways serve as potential therapeutic targets for glioblastoma. Clin Cancer Res; 22(14); 3513–23. ©2016 AACR.

21 June 2005 in The Journal of Physical Chemistry B
Verified
Journal Article
Closed access
KTKandasamy Thirunavukkarsu
Kandasamy Thirunavukkarsu
KTKrishnan Thirumoorthy
Krishnan Thirumoorthy
JLJörg Libuda
Jörg Libuda
CGChinnakonda S. Gopinath
Chinnakonda S. Gopinath

1 July 2016 in Dalton Transactions
Verified
Journal Article
Closed access
PDF file
KSKabali Senthilkumar
Kabali Senthilkumar
KTKrishnan Thirumoorthy
Krishnan Thirumoorthy
Claudia DragonettiClaudia Dragonetti
Claudia Dragonetti
DMDaniele Marinotto
Daniele Marinotto
SRStefania Righetto
Stefania Righetto
NPNallasamy Palanisami
Nallasamy Palanisami
The first example of a Y-shaped ferrocene quinoxaline derivative with high and stable SHG response in polymeric films is reported.

26 October 2018 in The Journal of Physical Chemistry A
Verified
Journal Article
Closed access
KTKrishnan Thirumoorthy
Krishnan Thirumoorthy
Amir KartonAmir Karton
Amir Karton
Venkatesan S. ThimmakonduVenkatesan S. Thimmakondu
Venkatesan S. Thimmakondu